首站-论文投稿智能助手
典型文献
Screening strategy and time points for newborn hearing re-screening with high risk factors
文献摘要:
Objective::To compare and analyze the pass rate and screening strategy of hearing rescreening for newborns with high risk factors.Methods::Retrospective chart review of high-risk newborns who failed their initial newborn hearing screen and subsequently underwent secondary hearing tests from June 2011 to June 2018 in Guangzhou Women and Children's Medical Center were performed.Results::Eight hundred and sixty-eight newborns with high risk factors were included in the study. The 57-70 days (83.5%) and 71-84 days (83.4%) group had the highest pass rate compared with 42-56 days (75.8%) and < 42 days (68.3%) group. As for different screening strategies, the pass rate of OAE(otoacoustic emissions), AABR (auto auditory brainstem response) and OAE + AABR was the highest in 57-70 days group and 71-84 days group, respectively. The OAE + AABR had the lowest pass rate compared to the other two modalities. When the pass rate was compared as different risk factors, the 57-70 days and 71-84 days group also had the highest pass rate compared with 42-56 days and < 42 days group and the pass rate had no significant differences among various risk factors group.Conclusion::Our results showed that all the pass rate of OAE, AABR and OAE+ AABR was the highest in 57-70 days group and 71-84 days group with significant difference, suggesting that the delayed screening time (>57 days) may increase the re-screening pass rate and reduce anxiety of parents, which is of great significance for clinical work.
文献关键词:
Auto auditory brainstem response;Hearing screening;Newborns;Otoacoustic emissions
作者姓名:
Zeng Qing-Xiang;Luo Ren-Zhong;Yan Sheng-Bao;Tang Yi-Quan;Wen Rui-Jin;Liu Wen-Long
作者机构:
Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical College, Guangzhou, China
引用格式:
[1]Zeng Qing-Xiang;Luo Ren-Zhong;Yan Sheng-Bao;Tang Yi-Quan;Wen Rui-Jin;Liu Wen-Long-.Screening strategy and time points for newborn hearing re-screening with high risk factors)[J].世界耳鼻咽喉头颈外科杂志(英文),2022(03):257-261
A类:
rescreening,OAE+,Newborns
B类:
Screening,strategy,points,hearing,risk,factors,Objective,To,analyze,pass,newborns,Methods,Retrospective,chart,review,who,failed,their,initial,subsequently,underwent,secondary,tests,from,June,Guangzhou,Women,Children,Medical,Center,were,performed,Results,Eight,hundred,sixty,eight,included,study,days,group,had,highest,compared,different,strategies,otoacoustic,emissions,AABR,auto,auditory,brainstem,response,was,respectively,lowest,other,two,modalities,When,also,no,significant,differences,among,various,Conclusion,Our,results,showed,that,all,suggesting,delayed,may,increase,reduce,anxiety,parents,which,great,significance,clinical,work,Auto,Hearing,Otoacoustic
AB值:
0.410313
相似文献
Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China
Chunli Zhang;Wei Wan;Shuai Zhang;Jingwen Wang;Ru Feng;Jiangtao Li;Junyue Chai;Hebing Zhou;Liru Wang;Yuping Zhong;Xiaodong Mo;Mengzhu Shen;Hongmei Jing;Hui Liu-Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Hematology,Beijing No.6 Hospital,Beijing 100007,China;Department of Hematology,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Department of Hematology,Fuxing Hospital,Capital Medical University,Beijing 100038,China;Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100043,China;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China
Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA
Kenan Zhang;Xing Liu;Guanzhang Li;Xin Chang;Shouwei Li;Jing Chen;Zheng Zhao;Jiguang Wang;Tao Jiang;Ruichao Chai-Department of Molecular Pathology,Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China;Department of Neuropathology,Beijing Neurosurgical Institute,Capital Medical University,Beijing 100070,China;Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China;Department of Neurosurgery,Beijing Sanbo Brain Hospital,Capital Medical University,Beijing 100093,China;Division of Life Science and State Key Laboratory of Molecular Neuroscience,Department of Chemical and Biological Engineering,The Hong Kong University of Science and Technology,Clear Water Bay,Kowloon,Hong Kong SAR 999077,China;Hong Kong Center for Neurodegenerative Diseases,Hong Kong Science Park,Hong Kong SAR 999077,China;HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute,Futian,Shenzhen 518057,China
Homeopathy for COVID-19 in primary care:A randomized,double-blind,placebo-controlled trial(COVID-Simile study)
Ubiratan Cardinalli Adler;Maristela Schiabel Adler;Ana Elisa Madureira Padula;Livia Mitchiguian Hotta;Amarilys de Toledo Cesar;José Nelson Martins Diniz;Helen de Freitas Santos;Edson Zangiacomi Martinez-Department of Medicine,Federal University of S?o Carlos,S?o Carlos 13565-905,Brazil;Homeopathy Solidarity Outpatient Extension Program,Mackenzie Presbyterian University,S?o Paulo 01302-907,Brazil;Municipal Center for Integrative and Complementary Practices in Health,Guarulhos 07023-051,Brazil;HN-Cristiano Institute,S?o Paulo 02013-001,Brazil;School Health Unit,Federal University of S?o Carlos,Sao Carlos 13565-905,Brazil;Federal Institute of Education,Science and Technology of S?o Paulo,Birigui 16201-407,Brazil;Department of Social Medicine,Ribeir?o Preto Medical School,University of Sao Paulo,Ribeirao Preto 14049-900,Brazil
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Bi Hanxin;Chen Xingxing;Chen Yuxin;Zhao Xin;Wang Shasha;Wang Jiehong;Lyu Ting;Han Shuang;Lin Tao;Li Mingquan;Yuan Donghong;Liu Junye;Shi Yongquan-Xi’an Medical University, Xi’an, Shaanxi 710021, China;State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi 710032, China;Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Xi’an Red Cross Hospital, Xi’an, Shaanxi 710054, China;Department of Gastroenterology, Xi’an Daxing Hospital, Xi’an, Shaanxi 710082, China;Department of Gastroenterology, Yan’an People’s Hospital, Yan’an, Shaanxi 716000, China;Department of Gastroenterology, Yan’an University Affiliated Hospital, Yan’an, Shaanxi 716000, China;Department of Radiation Protective Medicine, Air Force Medical University, Xi’an, Shaanxi 710032, China
Anatomical morphology of the aortic valve in Chinese aortic stenosis patients and clinical results after downsize strategy of transcatheter aortic valve replacement
Niu Guannan;Ali Walid Ben;Wang Moyang;Jilaihawi Hasan;Zhang Haitong;Zhang Qian;Ye Yunqing;Liu Xinmin;Yao Jing;Zhao Qinghao;Wang Yubin;Zhou Zheng;Zhang Lizhi;Ren Xinshuang;An Yunqiang;Lu Bin;Modine Thomas;Wu Yongjian;Song Guangyuan-Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, China;Structural Heart Intervention Program, Department of Surgery, Montreal Heart Institute, Montreal H1T 1C8, Quebec, Canada;Heart Valve Center, NYU Langone Health, New York, NY 10016, USA;Interventional Center of Valvular Heart Disease, Anzhen Hospital Affiliate of Capital University of Medical Sciences, Beijing 100029, China;Eagles Corelab., YingKe Medical (Beijing) Co., Ltd, Beijing 100160, China;Department of Radiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;Service Médico-Chirurgical: Valvulopathies-Chirurgie Cardiaque-Cardiologie Interventionelle Structurelle, H?pital Cardiologique de Haut Lévèque, CHU Bordeaux, Bordeaux 33000, France
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。